Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases

Abstract

The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof is administered in an amount sufficient to down-regulate the levels of antinuclear antibodies. A further aspect of the invention relates to a combination comprising an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, such as SLE.

The invention claimed is: 
     
       1. A combination comprising roscovitine, or a pharmaceutically acceptable salt thereof, and methylprednisolone. 
     
     
       2. A pharmaceutical product comprising roscovitine, or a pharmaceutically acceptable salt thereof, and methylprednisolone as a combined preparation for simultaneous, sequential or separate use in therapy. 
     
     
       3. A pharmaceutical product according to  claim 2  which further comprises a pharmaceutically acceptable carrier, diluent or excipient. 
     
     
       4. A method of treating systemic lupus erythematosis (SLE), the method comprising administering to a subject in need thereof a sufficient amount of a pharmaceutical product according to  claim 2 . 
     
     
       5. A method according to  claim 4  wherein the roscovitine, or pharmaceutically acceptable salt thereof, and methylprednisolone are administered simultaneously, separately or sequentially. 
     
     
       6. A method according to  claim 4  which comprises administering the roscovitine, or pharmaceutically acceptable salt thereof, to a subject prior to sequentially or separately administering methylprednisolone to said subject. 
     
     
       7. A method according to  claim 4  which comprises administering methylprednisolone to a subject prior to sequentially or separately administering the roscovitine, or pharmaceutically acceptable salt thereof. 
     
     
       8. A method according to  claim 4  wherein the roscovitine, or pharmaceutically acceptable salt thereof, and methylprednisolone are each administered in a therapeutically effective amount with respect to the individual components. 
     
     
       9. A method according to  claim 4  wherein the roscovitine, or pharmaceutically acceptable salt thereof, and methylprednisolone are each administered in a subtherapeutic amount with respect to the individual components.